Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Profile of patients treated with omalizumab in routine clinical practice in Spain.

Ancochea J, Chivato T, Casan P, Picado C, Herráez L, Casafont J.

Allergol Immunopathol (Madr). 2014 Mar-Apr;42(2):102-8. doi: 10.1016/j.aller.2012.10.010.

PMID:
23267505
2.

Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.

Tzortzaki EG, Georgiou A, Kampas D, Lemessios M, Markatos M, Adamidi T, Samara K, Skoula G, Damianaki A, Schiza S, Tzanakis N, Siafakas NM.

Pulm Pharmacol Ther. 2012 Feb;25(1):77-82. doi: 10.1016/j.pupt.2011.11.004.

PMID:
22155001
3.

Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).

Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM; QUALITX Study Investigators..

J Asthma. 2012 Apr;49(3):288-93. doi: 10.3109/02770903.2012.660297.

PMID:
22356355
4.

[Retrospective analysis of omalizumab in patients with severe allergic asthma].

Padullés Zamora N, Comas Sugrañes D, Méndez Cabaleiro N, Figueras Suriol A, Jodar Masanes R.

Farm Hosp. 2013 Sep-Oct;37(5):399-405. doi: 10.7399/FH.2013.37.5.728. Spanish.

5.

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.

Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N.

Pharmacoeconomics. 2012 Nov 1;30(11):991-1004. doi: 10.2165/11597160-000000000-00000. Review.

PMID:
22950547
6.

Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma.

Pelaia G, Gallelli L, Romeo P, Renda T, Busceti MT, Proietto A, Grembiale RD, Marsico SA, Maselli R, Vatrella A.

Int J Clin Pharmacol Ther. 2011 Dec;49(12):713-21.

PMID:
22122813
7.

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W.

Ann Intern Med. 2011 May 3;154(9):573-82. doi: 10.7326/0003-4819-154-9-201105030-00002.

8.

Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.

Chen H, Eisner MD, Haselkorn T, Trzaskoma B.

Respir Med. 2013 Jan;107(1):60-7. doi: 10.1016/j.rmed.2012.09.008.

9.

[Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab].

Pacheco-Galván A, Hinojosa-Macías M, Hurtado-Barbudo B, González-Cervera J, Sueiro-Bendito A.

Med Clin (Barc). 2009 Oct 3;133(12):460-3. doi: 10.1016/j.medcli.2009.07.011. Spanish.

PMID:
19775710
10.

Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.

Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G.

Respir Med. 2008 Oct;102(10):1371-8. doi: 10.1016/j.rmed.2008.06.002.

11.

Association between consistent omalizumab treatment and asthma control.

Lafeuille MH, Gravel J, Zhang J, Gorsh B, Figliomeni M, Lefebvre P.

J Allergy Clin Immunol Pract. 2013 Jan;1(1):51-7. doi: 10.1016/j.jaip.2012.08.006.

PMID:
24229822
12.

Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy.

Velling P, Skowasch D, Pabst S, Jansen E, Tuleta I, Grohé C.

Eur J Med Res. 2011 Sep 12;16(9):407-10.

13.

Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.

Özgür ES, Özge C, Ïlvan A, Naycı SA.

J Asthma. 2013 Aug;50(6):687-94. doi: 10.3109/02770903.2013.792348.

PMID:
23557459
14.

Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.

Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

Ann Allergy Asthma Immunol. 2012 Jul;109(1):59-64. doi: 10.1016/j.anai.2012.04.015.

PMID:
22727159
15.

Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs.

Costello RW, Long DA, Gaine S, Mc Donnell T, Gilmartin JJ, Lane SJ.

Ir J Med Sci. 2011 Sep;180(3):637-41. doi: 10.1007/s11845-011-0716-2.

PMID:
21557095
16.

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P.

Pediatrics. 2001 Aug;108(2):E36.

PMID:
11483846
17.

Omalizumab in the treatment of asthma.

Tan R, Corren J.

Expert Rev Respir Med. 2011 Dec;5(6):747-56. doi: 10.1586/ers.11.73. Review.

PMID:
22082161
18.

Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma.

Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J, Molimard M, Abenhaim L; Pharmacoepidemiology of Asthma and Xolair (PAX) Study Group..

Chest. 2013 Feb 1;143(2):398-405.

PMID:
23505637
19.

[Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].

Shitrit D, Talker O, Metabichek A, Yaakovi I.

Harefuah. 2012 Apr;151(4):216-9, 254, 253. Hebrew.

PMID:
22616149
20.
Items per page

Supplemental Content

Support Center